SCARLETT IDEMA: Open Payments
NPI 1316520653 · DETROIT, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$664 in 26 payments from 10 companies in 2025. Trend: 2023 $20 · 2024 $284 · 2025 $664
Food & beverage: $664
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 15 | $431 |
| Novo Nordisk Inc | 2 | $45 |
| Cipher Pharmaceuticals US LLC | 1 | $42 |
| Verona Pharma, Inc. | 2 | $33 |
| ABIOMED | 1 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| GlaxoSmithKline, LLC. | 1 | $17 |
| Organon LLC | 1 | $17 |
| Phadia US Inc. | 1 | $16 |
| Gilead Sciences, Inc. | 1 | $16 |
Products named: REZDIFFRA, Ozempic, Natroba, Ohtuvayre, AUSTEDO XR, BEXSERO, NEXPLANON, ImmunoCAP.
Industry payments across MI — which companies pay providers there.
